Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1680-1685

  Finckh, Axel ^a   Möller, Burkhard ^b   Dudler, Jean ^c   Walker, Ulrich A ^d   Kyburz, Diego ^e   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Fribourg Hospital   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE REGISTRY; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEALTH ASSESSMENT QUESTIONNAIRE SCORE; HUMAN; JOINT INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RATINGEN EROSION SCORE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; HUMANS; JOINTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866129746     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201016     Document Type: Article

References (28)

1. Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology clinical trial priorities and design conference, July 22-23, 2010. Arthritis Rheum 201163:2151-6.
2. Finckh A. Comparative effectiveness of rheumatoid arthritis therapies. Curr Rheumatol Rep 2010;12:348-54.
3. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
4. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
5. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
6. Blom M, Kievit W, Donders AR, et al. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol 2011;38:2355-61.
7. Emery P, Sarzi-Puttini P, Moots R, et al. Relative effectiveness of rituximab and an alternative TNF inhibitor in patients with rheumatoid arthritis who had experienced an insufficient response or intolerance to a single previous TNF inhibitor: interim results from a global comparative-effectiveness observational study. Annual Scientific Meeting of the American College of Rheumatology, 2011, Chicago. Arthritis Rheum 2011;63:S45.
8. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010;22:321-9.
9. Kekow J, Mueller-Ladner U, Link R, et al. Real life treatment with rituximab in TNF blocker non-responders is superior to treatment with a second TNF blocker. Annual Scientific Meeting of the American College of Rheumatology (ACR), 2010, Atlanta. Arthritis Rheum 2010;S406.
10. Ancuta I, Codreanu C, Ionescu R, et al. Rituximab after TNF inhibitors - analysis of real life RA treatment practice. Annual European Congress of Rheumatology, 2011, London. Ann Rheum Dis 2011;69:FRI0360.
11. Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009;11:R163.
12. van der Heijde DM. Radiographic imaging: the 'gold standard' for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford) 2000;39(Suppl 1):9-16.
13. Landewé R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
14. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
15. van der Heijde DM. Overview of radiologic efficacy of new treatments. Rheum Dis Clin North Am 2004;30:285-93, vi.
16. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
17. Uitz E, Fransen J, Langenegger T, et al. Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford) 2000;39:542-9.
18. Kobelt G, Kasteng R. Access to innovative treatments in rheumatoid arthritis in Europe: uptake of biologic treatments. Report for the European Federation of Pharmaceutical Industry Associations (EFPIA), 2009. http://www.efpia.eu/Content/Default.asp?PageID=559&DocID=7640 (accessed date 8 August 2011).
19. Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-602.
20. Rau R, Wassenberg S, Herborn G, et al. A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol 1998;25:2094-107.
21. Creemers M, Fransen J, Van Riel P. Reliability and sensitivity to change of the Ratingen joint damage score in a cohort of early RA patients. Annual European Meeting of Rheumatology, 2006, Amsterdam. Ann Rheum Dis 2006;S165.
22. Loiero D. Inter- and Intrareader Variability of Ratingen Score in the SCQM Database and Its Causes. Zurich: University of Zurich, 2011.
23. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
24. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006;54:54-9.
25. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
26. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
27. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
28. de Punder YM, van Riel PL. Rheumatoid arthritis: understanding joint damage and physical disability in RA. Nat Rev Rheumatol 2011;7:260-1.